CAJ | 학술논문

中期18 F-FDG PET-CT 能提供代谢功能和形态学的双重信息，成为评估淋巴瘤患者疗效及其预后最为敏感的手段，也成为指导临床试验设计及改变临床应用的依据。目前，如何合理化应用中期18 F-FDG PET-CT 仍存在争议。
중기18 F-FDG PET-CT 능제공대사공능화형태학적쌍중신식，성위평고림파류환자료효급기예후최위민감적수단，야성위지도림상시험설계급개변림상응용적의거。목전，여하합이화응용중기18 F-FDG PET-CT 잉존재쟁의。
Interim fluorine 1 8 fluorodeoxyglucose (1 8 F-FDG)positron emission tomography (PET) integrated with computed tomography (CT) provides both metabolic and morphologic information,which becomes one of the most sensitive tools to evaluate the efficacy of the therapy and predict the prognosis of patients with lymphoma.Meanwhile,it is the basis for guiding trial design and changing clinical practice.How-ever,it is still a controversial issue in the ideal utilization of interim 1 8 F-FDG PET-CT imaging for the patients with lymphoma.